Feel free to use our complete database with charts, tables and examples.
> Information on switching, tapering or discontinuing an antidepressant.
Serotonin Reuptake Inhibitors - SSRIs Select this option for any of the following:
See link above for additional information on discontinuing an antidepressant or performing a cross-taper.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Select this option for any of the following:
Tricyclic antidepressants (TCAs) Select this option for any of the following:
Norepinephrine and Dopamine Reuptake Inhibitor (NDRI) Select this option for any of the following:
Mixed Serotonergic Effects (Mixed 5-HT) Select this option for any of the following:
Serotonin and α2-Adrenergic Antagonist Select this option for any of the following:
Monoamine Oxidase Inhibitors (MAOIs)
> https://www.newmedicalterms.com/drugs/antidepressant-discontinuation-syndrome/
Cleare A, Pariante CM, Young AH et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459-525. [PubMed: 25969470]
Cipriani A, Forukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet. 2018;391:1357-1366. [PubMed: 29477251]
Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR*D study: Treating depression in the real world. Cleve Clin J Med. 2008;75(1):57-66. [PubMed:18236731]
Hasin DS, Sarvet AL, Meyers JL et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the united states. JAMA Psychiatry. 2018;75(4):336-346. [PubMed: 29450462]
Kok RM, Reynolds CF. Management of depression in older adults: A review. JAMA. 2017;317(20):2114-2122. [PubMed: 28535241]
La Torre A, Giupponi G, Duffy D, Conca A. Sexual dysfunction related to psychotropic drugs: A critical review—part I: Antidepressants. Pharmacopsychiatry. 2013;46(5):191-199. [PubMed: 23737245]
Mann JJ. The medical management of depression. N Engl J Med. 2005;353(17):1819-1834. [PubMed: 16251538]
McIntyre RS. The role of new antidepressants in clinical practice in Canada: A brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat. 2017;13:2913-2919. [PubMed: 29238196]
Mohamed S, Johnson GR, Chen P et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment. The VAST-D randomized clinical trial. JAMA. 2018;318:132-145.
Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomics testing improve clinical outcomes for major depressive disorder. A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry. 2017;78(6):720-729. [PubMed: 28068459]
Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: Review and meta-analysis. Am J Psychiatry. 2000;157(10):1552-1562. https://pubmed.ncbi.nlm.nih.gov/11007705/.
Stone EA, Lin Y, Quartermain D. A final common pathway for depression? Progress toward a general conceptual framework. Neurosci Biobehav Rev . 2008;32(3):508-524. [PubMed: 18023876]
Taylor C, Fricker AD, Devi L, et al. Mechanisms of action of antidepressants: From neurotransmitter systems to signaling pathways. Cell Signal. 2005;17(5):549-557. PubMed: 15683730]].